Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries CLASS ACTION UPDATE for CCIV, ATVI and ITRM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders By: Levi & Korsinsky, LLP via AccessWire August 12, 2021 at 10:30 AM EDT NEW YORK, NY / ACCESSWIRE / August 12, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.CCIV Shareholders Click Here: https://www.zlk.com/pslra-1/churchill-capital-corp-iv-information-request-form?prid=18485&wire=1ATVI Shareholders Click Here: https://www.zlk.com/pslra-1/activision-blizzard-inc-loss-submission-form?prid=18485&wire=1ITRM Shareholders Click Here: https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=18485&wire=1* ADDITIONAL INFORMATION BELOW *Churchill Capital Corp IV (NYSE:CCIV)CCIV Lawsuit on behalf of: investors who purchased January 11, 2021 - February 22, 2021Lead Plaintiff Deadline : August 30, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/churchill-capital-corp-iv-information-request-form?prid=18485&wire=1According to the filed complaint, during the class period, Churchill Capital Corp IV made materially false and/or misleading statements and/or failed to disclose that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.Activision Blizzard, Inc. (NASDAQ:ATVI)ATVI Lawsuit on behalf of: investors who purchased August 4, 2016 - July 27, 2021Lead Plaintiff Deadline : October 4, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/activision-blizzard-inc-loss-submission-form?prid=18485&wire=1According to the filed complaint, during the class period, Activision Blizzard, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Activision Blizzard discriminated against women and minority employees; (2) Activision Blizzard fostered a pervasive "frat boy" workplace culture that continues to thrive; (3) numerous complaints about unlawful harassment, discrimination, and retaliation were made to human resources personnel and executives which went unaddressed; (4) the pervasive culture of harassment, discrimination, and retaliation would result in serious impairments to Activision Blizzard's operations; (5) as a result of the foregoing, the Company was at greater risk of regulatory and legal scrutiny and enforcement, including that which would have a material adverse effect; (6) Activision Blizzard failed to inform shareholders that the California Department of Fair Employment and Housing had been investigating Activision Blizzard for harassment and discrimination; and (7) as a result, Defendants' statements about Activision Blizzard's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.Iterum Therapeutics Plc (NASDAQ:ITRM)ITRM Lawsuit on behalf of: investors who purchased November 30, 2020 - July 23, 2021Lead Plaintiff Deadline : October 4, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=18485&wire=1According to the filed complaint, during the class period, Iterum Therapeutics Plc made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.Eduard Korsinsky, Esq.55 Broadway, 10th FloorNew York, NY 10006jlevi@levikorsinsky.comTel: (212) 363-7500Fax: (212) 363-7171www.zlk.comSOURCE: Levi & Korsinsky, LLPView source version on accesswire.com: https://www.accesswire.com/659488/CLASS-ACTION-UPDATE-for-CCIV-ATVI-and-ITRM-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
CLASS ACTION UPDATE for CCIV, ATVI and ITRM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders By: Levi & Korsinsky, LLP via AccessWire August 12, 2021 at 10:30 AM EDT NEW YORK, NY / ACCESSWIRE / August 12, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.CCIV Shareholders Click Here: https://www.zlk.com/pslra-1/churchill-capital-corp-iv-information-request-form?prid=18485&wire=1ATVI Shareholders Click Here: https://www.zlk.com/pslra-1/activision-blizzard-inc-loss-submission-form?prid=18485&wire=1ITRM Shareholders Click Here: https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=18485&wire=1* ADDITIONAL INFORMATION BELOW *Churchill Capital Corp IV (NYSE:CCIV)CCIV Lawsuit on behalf of: investors who purchased January 11, 2021 - February 22, 2021Lead Plaintiff Deadline : August 30, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/churchill-capital-corp-iv-information-request-form?prid=18485&wire=1According to the filed complaint, during the class period, Churchill Capital Corp IV made materially false and/or misleading statements and/or failed to disclose that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.Activision Blizzard, Inc. (NASDAQ:ATVI)ATVI Lawsuit on behalf of: investors who purchased August 4, 2016 - July 27, 2021Lead Plaintiff Deadline : October 4, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/activision-blizzard-inc-loss-submission-form?prid=18485&wire=1According to the filed complaint, during the class period, Activision Blizzard, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Activision Blizzard discriminated against women and minority employees; (2) Activision Blizzard fostered a pervasive "frat boy" workplace culture that continues to thrive; (3) numerous complaints about unlawful harassment, discrimination, and retaliation were made to human resources personnel and executives which went unaddressed; (4) the pervasive culture of harassment, discrimination, and retaliation would result in serious impairments to Activision Blizzard's operations; (5) as a result of the foregoing, the Company was at greater risk of regulatory and legal scrutiny and enforcement, including that which would have a material adverse effect; (6) Activision Blizzard failed to inform shareholders that the California Department of Fair Employment and Housing had been investigating Activision Blizzard for harassment and discrimination; and (7) as a result, Defendants' statements about Activision Blizzard's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.Iterum Therapeutics Plc (NASDAQ:ITRM)ITRM Lawsuit on behalf of: investors who purchased November 30, 2020 - July 23, 2021Lead Plaintiff Deadline : October 4, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=18485&wire=1According to the filed complaint, during the class period, Iterum Therapeutics Plc made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.Eduard Korsinsky, Esq.55 Broadway, 10th FloorNew York, NY 10006jlevi@levikorsinsky.comTel: (212) 363-7500Fax: (212) 363-7171www.zlk.comSOURCE: Levi & Korsinsky, LLPView source version on accesswire.com: https://www.accesswire.com/659488/CLASS-ACTION-UPDATE-for-CCIV-ATVI-and-ITRM-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders